PAVmed Successfully Completes Clinical Safety Study Procedures for CarpX™ 510(k) Re-submission
August 15, 2019 09:30 ET
|
PAVmed Inc.
All 20 patients underwent successful CarpX procedures while passing primary effectiveness endpoint, with all follow-up patients to date passing primary safety endpoint NEW YORK, Aug. 15, 2019 ...
PAVmed to Hold Business Update Conference Call on May 21, 2019
May 06, 2019 09:30 ET
|
PAVmed Inc.
NEW YORK, May 06, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the...